Skip Navigation


Hum. Reprod. Advance Access originally published online on May 27, 2004
Human Reproduction 2004 19(8):1741-1745; doi:10.1093/humrep/deh319
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
19/8/1741    most recent
deh319v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by van Wely, M.
Right arrow Articles by Bossuyt, P.M.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Wely, M.
Right arrow Articles by Bossuyt, P.M.M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction vol. 19 no. 8 © European Society of Human Reproduction and Embryology 2004; all rights reserved

An economic comparison of a laparoscopic electrocautery strategy and ovulation induction with recombinant FSH in women with clomiphene citrate-resistant polycystic ovary syndrome

M. van Wely1,3, N. Bayram1, F. van der Veen1 and P.M.M. Bossuyt2

1 Center for Reproductive Medicine, Department of Obstetrics and Gynaecology (H4-205), and 2 Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, P.O.Box 22700, 1100 DE Amsterdam, The Netherlands

3 To whom correspondence should be addressed. Email: m.vanwely{at}amc.uva.nl

BACKGROUND: Recombinant FSH (rFSH) is the current standard treatment for ovulation induction in women with polycystic ovary syndrome (PCOS) that do not respond to clomiphene citrate. Ovulation induction with rFSH is known to be costly due to the necessity of daily injections and intensive monitoring. An alternative strategy, starting with electrocautery of the ovaries, may be a less costly option. METHODS: An economic evaluation was set up alongside a multicentre randomized clinical trial comparing laparoscopic electrocautery of the ovaries, followed by clomiphene citrate and rFSH when anovulation persisted, and treatment with rFSH in 168 women with clomiphene citrate-resistant PCOS. Data on resources used for treatment and productivity loss were collected prospectively up to an eventual ongoing pregnancy with a time horizon of 12 months. RESULTS: At 12 months the ongoing pregnancy rates were 67% for both the electrocautery strategy and rFSH treatment. Mean total costs per woman were {euro}5308 for the electrocautery strategy and {euro}5925 for treatment with rFSH, resulting in a mean difference of {euro}617 (95% CI: –{euro}382 to {euro}1614). CONCLUSIONS: The total treatment costs up to an ongoing pregnancy are comparable for rFSH treatment and an alternative strategy starting with electrocautery. Due to a lower number of multiple pregnancies, the electrocautery strategy can be expected to result in lower total costs when costs of the delivery are included.

Key words: cost minimization/gonadotrophin/laparoscopic electrocautery/ovulation induction/PCOS


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens
Consensus on infertility treatment related to polycystic ovary syndrome
Hum. Reprod., March 1, 2008; 23(3): 462 - 477.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. J.C. Eijkemans, S. Polinder, A. G.M.G.J. Mulders, J. S.E. Laven, J.D. F. Habbema, and B. C.J.M. Fauser
Individualized cost-effective conventional ovulation induction treatment in normogonadotrophic anovulatory infertility (WHO group 2)
Hum. Reprod., October 1, 2005; 20(10): 2830 - 2837.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. van Wely, N. Bayram, F. van der Veen, and P. Bossuyt
Reply to: Are laparoscopic ovarian diathermy and gonadotropin administration the only therapeutic second-steps in clomiphene-citrate resistant women with polycystic ovary syndrome?
Hum. Reprod., November 1, 2004; 19(11): 2683 - 2683.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.